CHINA NATIONAL MEDICINES CORP (600511) Q1 2025 earnings summary

Executive summary

• Revenue for Q1 2025 reached RMB 12.71 billion, up 4.87% year-over-year; net profit attributable to shareholders was RMB 459 million, down 0.10% year-over-year.

• Basic and diluted EPS were RMB 0.6084, nearly flat from the prior year.

• Cash flow from operating activities was negative RMB 1.89 billion, a further decline from the previous year.

Financial highlights

• Total assets at quarter-end were RMB 35.10 billion, up 0.48% from year-end 2024.

• Shareholders' equity attributable to listed company shareholders rose 2.68% to RMB 17.59 billion.

• Non-recurring profit and loss items contributed RMB 12.78 million to net profit.

• Gross margin remained stable as cost increases were in line with revenue growth.

Key financial ratios and metrics

• Weighted average ROE was 2.64%, down 0.23 percentage points year-over-year.

• Basic and diluted EPS both at RMB 0.6084, marginally lower than last year.

• Net cash outflow from operations increased to RMB 1.89 billion from RMB 1.72 billion year-over-year.